uniQure (NASDAQ:QURE) Director David Meek Sells 1,993 Shares

Posted by Stanley Muller on Jun 13th, 2026

uniQure N.V. (NASDAQ:QURE – Get Free Report) Director David Meek sold 1,993 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the transaction, the director owned 39,747 shares of the company’s stock, valued at approximately $1,075,553.82. The trade was a 4.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

uniQure Trading Up 2.8%

Shares of uniQure stock opened at $27.57 on Friday. The company has a fifty day simple moving average of $22.52 and a 200-day simple moving average of $21.80. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. On average, equities analysts forecast that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Institutional Trading of uniQure

Hedge funds have recently made changes to their positions in the company. Torren Management LLC acquired a new stake in shares of uniQure in the 4th quarter worth $28,000. Jones Financial Companies Lllp lifted its stake in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the period. IFP Advisors Inc acquired a new stake in shares of uniQure in the 4th quarter worth $48,000. Smartleaf Asset Management LLC acquired a new stake in shares of uniQure in the 4th quarter worth $48,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in shares of uniQure in the 3rd quarter worth $50,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

QURE has been the subject of several research reports. Cantor Fitzgerald reiterated a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a research report on Tuesday, May 5th. HC Wainwright reduced their price target on shares of uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, Wolfe Research initiated coverage on shares of uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.83.

Read Our Latest Stock Analysis on QURE

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.